Physician profile
Cara Barber
NPI 1508424433
$5,765.76
in general payments reported to CMS, 2019-2025
21 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $344 · 2022: $1,249 · 2023: $1,881 · 2024: $1,126 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,090.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,668.09 | 2022-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $840.03 | 2024-2025 | Tremfya |
| Galderma Laboratories, L.P. | $390.76 | 2023-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $301.76 | 2022-2023 | Vtama |
| Lilly USA, LLC | $297.91 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $267.79 | 2022-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.95 | 2023-2025 | Spevigo, Cyltezo |
| Genzyme Corporation | $233.91 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $200.36 | 2022-2024 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $148.00 | 2023-2024 | Zoryve |
| Ucb, INC. | $123.86 | 2023-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $102.67 | 2025 | |
| Sun Pharmaceutical Industries INC. | $59.52 | 2024-2025 | Winlevi |
| Novartis Pharmaceuticals Corporation | $56.05 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $49.31 | 2024 | Tremfya |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $28.46 | 2025 | Nuzyra |
| Helsinn Therapeutics (U.S.), INC. | $28.00 | 2022 | |
| Incyte Corporation | $21.77 | 2025 | Opzelura |
| Blueprint Medicines Corporation | $21.09 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.02 | 2025 | Cabtreo |
| Merz North America, INC. | $18.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Barber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.